biostudies-literatureUnknown61(6)Violet J¹⁷⁷Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resistant prostate cancer. We now report their longer-term outcomes, including a 20-patient extension cohort and outcomes of subsequent systemic treatments after completion of trial therapy. <b>Methods:</b> Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed after standard therapies received up to 4 cycles of ¹⁷⁷Lu-PSMA every 6 wk. Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working Group 2), toxicity (ComJournal of nuclear medicine : official publication, Society of Nuclear Medicine857-865https://www.ebi.ac.uk/biostudies/studies/S-EPMC7262220biostudies-literatureLong-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.PMC7262220Sandhu SKumar ARJackson PEu PHicks RJTran BScalzo MFerdinandus JHofman MSKong GIravani APattison DAMooi JViolet JKalff VThang SPAkhurst TBeaulieu AMurphy DGGuo CWilliams SfalseLong-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.¹⁷⁷Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resistant prostate cancer. We now report their longer-term outcomes, including a 20-patient extension cohort and outcomes of subsequent systemic treatments after completion of trial therapy. <b>Methods:</b> Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed after standard therapies received up to 4 cycles of ¹⁷⁷Lu-PSMA every 6 wk. Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working Group 2), toxicity (Com2020-01-01T00:00:00Z2020 Jun2026-04-30T08:19:13.555Z2021-02-21T01:07:51ZS-EPMC72622203173267610.2967/jnumed.119.236414